The announcement of a class action lawsuit for alleged securities fraud is likely to create negative sentiment among investors, potentially leading to a decline in the stock price of Kyverna Therapeutics, Inc. in the short term. Legal issues of this nature can cause uncertainty and concern about the company's financial health and governance.